Navigation Links
Vion Pharmaceuticals Receives a Standard Review from the FDA for Its New Drug Application for Onrigin(TM)
Date:4/23/2009

NEW HAVEN, Conn., April 23 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced that the New Drug Application (NDA) for its lead oncology therapeutic Onrigin(TM) (laromustine) Injection has received a standard review classification by the U.S. Food and Drug Administration (FDA). Therefore, a user fee goal date of December 12, 2009 for a decision by the FDA with respect to the approval of the Company's NDA has been established.

The Company had previously announced the acceptance of the NDA filing for review by the FDA on April 16, 2009. The NDA presents data for Onrigin(TM) as a single agent for remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML). The NDA is based on the results of an international multi-center pivotal Phase II trial of 85 patients sixty years of age or older with de novo poor-risk AML, supplemented by data from 55 patients in a previous Phase II trial in elderly AML. Eighty-six percent of these 140 patients had two or more risk factors that predicted for a poor prognosis.

Alan Kessman, Chief Executive Officer, commented, "Our level of excitement continues to grow as we move forward in the FDA's process of reviewing our NDA. We will continue to work closely with the FDA on the filing with the objective of achieving approval for Onrigin(TM) in its first indication in the United States." He added, "The positive news today is that we can expect to have an FDA decision this year."

About Vion Pharmaceuticals

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative oncology therapeutics. Vion has two agents in clinical trials, Onrigin(TM)(laromustine) Injection and Triapine(R). The FDA is reviewing a New Drug Applicat
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
2. Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
3. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
4. Genesis Pharmaceuticals Announces the Launch of Three TCM Products
5. Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research
6. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
7. Par Pharmaceutical Enters Into Agreement With Reliant Pharmaceuticals to Settle Patent Litigation Over Rythmol(R) SR
8. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
9. Strativa Pharmaceuticals Provides Product Pipeline Update
10. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2009 Financial Results
11. Amylin Pharmaceuticals Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... including having a discussion at home about how to prevent ... household, according to a study of the initial outbreak in ... issue of The Journal of Infectious Diseases , the ... influenza symptoms are often told to stay home from work ...
... parents of children with multiple medical problems, keeping up with ... can be overwhelming, especially for those in challenging socioeconomic situations. ... up using the emergency room, the country,s most expensive form ... But a growing concept in health care reform ...
... Reflecting the changing economic landscape, more older workers are staying in the work force, but increasingly in part-time rather than full-time jobs, according to new research released today ... ... ... ...
... survival doubled after the treatment, study found , TUESDAY, ... powerful regimen of radiation therapy kept early-stage lung tumors ... 56 percent of patients who underwent the therapy, called ... years after their treatment, according to preliminary findings from ...
... Highly-focused stereotactic body radiation therapy (SBRT) can ... and may ultimately improve survival for patients with ... findings of a Radiation Therapy Oncology Group study ... the Journal of the American Medical Association ...
... Carnegie Mellon University will host "Invention to Venture," a ... students interested in learning about what it takes to ... a wide range of topics including entrepreneurship, intellectual property ... assistant professor of engineering and public policy at Carnegie ...
Cached Medicine News:Health News:Preventive behaviors limited household transmission of H1N1 influenza during initial outbreak 2Health News:Preventive behaviors limited household transmission of H1N1 influenza during initial outbreak 3Health News:Novel 'medical home' program for pediatric patients, families cuts ER visits in half 2Health News:Novel 'medical home' program for pediatric patients, families cuts ER visits in half 3Health News:New Research from EBRI: Older Workers Trending Toward More Part-Time Work 2Health News:New Research from EBRI: Older Workers Trending Toward More Part-Time Work 3Health News:Radiation May Help Those With Inoperable Lung Tumors 2Health News:Radiation May Help Those With Inoperable Lung Tumors 3Health News:SBRT eliminates tumors with promising survival for early-stage inoperable lung cancer patients 2Health News:SBRT eliminates tumors with promising survival for early-stage inoperable lung cancer patients 3
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and ... addition of the "Inferior Vena Cava (IVC) Filters ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sector is projected to reach US$435 million by 2016. ... nearly 39% (2015) of the global value while ...
(Date:12/15/2014)... Norway , December 15, 2014 ... innovative drugs for aggressive drug resistant cancers, today announces ... in a private placing from new and existing investors. ... financing to support the development of its pipeline of ... program for its lead drug candidate, BGB324, a first-in-class ...
(Date:12/15/2014)... Dec. 15, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... been added to the NASDAQ Biotechnology Index (NBI). ... become effective upon market open on December 22, ... designed to track the performance of a set ... biotechnology or pharmaceutical according to the Industry Classification ...
Breaking Medicine Technology:Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4BerGenBio Completes NOK90 Million Fundraising 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4
... Jan. 18, 2011 Rochester Medical Corporation (Nasdaq: ... markets close on Tuesday, January 25, 2011.  The Company ... its earnings report.  The Company also plans to discuss ... 12, 2011.  The call will begin at 3:30 p.m. ...
... 18, 2011 Fenwal, Inc. of Lake Zurich, Illinois, ... signed an agreement under which Fenwal will co-market and ... plasma centers and hospitals in the United States and ... Genesis™ blood collection mixers and monitors, RapidSeal II™ tube ...
Cached Medicine Technology:Rochester Medical Announces First Quarter 2011 Earnings Conference Call Tuesday, January 25, 2011 2Fenwal, GenesisBPS Enter Agreement for Blood-Specialty Products 2
... Advanced Technologies, The UroMax Ultra ia ... of high pressure and low profile., ... yields a remarkably strong material that ... balloon materials., Non-Compliant Balloons, A compliant ...
... Fr Straight Channel; 33 or 42 cm ... Operating Ureteroscopes offer a small distal diameter ... to the ureter for diagnosis and treatment. ... ideal for large operating instruments, mechanical (Lithoclast) ...
... Small 6.9 Fr Diameter with Two ... ,MICRO-6L Long Semi-Rigid Ureteroscope, with a longer ... ureteroscope with two large working channels for ... allow you to basket a stone and ...
... The ACMI USA Series DUR-8 Durable Flexible ... the entire intrarenal collecting system with little ... superior secondary deflection allow complete intrarenal access, ... facilitates access to the proximal ureter and ...
Medicine Products: